Olink^® Proteomics Services for High-Throughput Biomarker Discovery

Olink^® Proteomics uses the Proximity Extension Assay (PEA) technology to quantify thousands of proteins simultaneously from minimal sample volumes. Each assay employs dual antibodies linked to DNA oligonucleotides that hybridize when bound to the same protein, enabling highly specific detection through next-generation sequencing (NGS) or qPCR readouts. This approach provides exceptional sensitivity, reproducibility, and scalability for biomarker discovery and validation.

Olink^® Explore HT, Explore, and Reveal services enable high-throughput profiling of over 5,000 proteins across hundreds of samples in a single run. By integrating Discovery’s automated workflows and in-house biorepository, researchers can shorten project timelines, identify novel biomarkers faster, and transition seamlessly to validation using Olink^® Target, Flex, and Focus platforms.

The Olink^® Explore and Reveal platforms support large-scale, discovery-phase proteomics, measuring thousands of proteins with broad coverage and minimal bias. Olink^® Target, Flex, and Focus are used for the next phase — targeted validation — allowing researchers to quantify specific biomarkers with high precision and customizable assay panels. Together, they provide an end-to-end proteomics workflow from discovery to validation.

Discovery Life Sciences combines Olink^® proteomic data with AI-driven bioinformatics to uncover patterns across large datasets. Machine learning models identify statistically significant biomarkers, classify patient subgroups, and predict biological pathways involved in disease mechanisms. This integrated approach enhances interpretability and translational value from high-throughput proteomic studies.

Olink^® assays are compatible with a wide range of sample matrices including plasma, serum, cerebrospinal fluid (CSF), urine, dried blood spots, conditioned media, and tissue biopsies. Discovery’s validated workflows ensure consistent performance across all matrices, enabling flexible study designs and longitudinal analysis.

Only 25 µL of sample is required for a full suite of Olink^® Explore proteins, and as little as 1 µL for selected Target or Reveal assays. Discovery’s automated handling minimizes waste while maintaining reproducibility across replicates.

Olink^® Proteomics supports biomarker discovery and translational research in oncology, cardiology, neurology, immunology, and metabolic disease. Discovery’s certified Olink^® services enable both exploratory and validation studies, supporting applications from early discovery to clinical biomarker verification.

Olink^® proteomic data can be seamlessly integrated with genomic, transcriptomic, and metabolomic datasets to provide a multi-dimensional understanding of disease mechanisms. Discovery’s unified multi-omic laboratory infrastructure supports such integration, helping researchers link protein expression patterns with underlying molecular drivers.

Discovery Life Sciences is a certified Olink^® service provider offering end-to-end support — from sample acquisition through biorepository access, proteomic analysis, and bioinformatic interpretation. With automated workflows and multi-omic lab integration, Discovery minimizes turnaround time and ensures reproducible, regulatory-grade data.